Screenshot 2021-10-14 at 9.02.35 AM
Thursday, March 19, 2026
28.4
C
Bengaluru
Hot topics
What about Indian Pharma?
Articles by K. Hariram, Vivek Hattangadi, Soham Wagh, Dr. Rajshri Jobanputra, and Rashesh Patel
Mounjaro to Orforglipro: Lilly’s $6 Billion Bet on the Next GLP‑1 Revolution
Eli Lilly is in a rare position. Its GLP-1...
Culture and Resistance to Change – A Pharma SFE Adoption Case Study
As an MNC Head, I was one among the...
Is Your Career Headed in the Right Direction?
Make Sure You're Moving in the Right Direction… Digital,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Hot topics
Is Indian Pharma Singing Digital Without Lyrics?
A large part of the pharma houses continues to...
72nd Republic Day: What’s the Road Ahead for Indian Pharma?
“We are getting too happy, for too little”: these...
THE ENCUBE ETHICALS PLAYBOOK: FROM GOA WORKSHOP TO $2BN+ GLOBAL DEAL
How a niche Indian topicals manufacturer outgrew its CDMO...
Interesting, Engaving & Relevant
In this issue Deepak Sharma talks about his journey from Medical Rep to Country Manager. Deeksha Fouzdar presents a case study on implementation of a competency-based HR system in Pharma. Other articles by K. Hariram and Vivek Hattangadi
Unmasking the Ethics of PCD Pharma Cos and the Incentives of Luxury Cars
🎁 The Diwali Dazzle: A Gilded Distraction?
In October 2025,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Excellence or Mediocrity—What Are You Building?
Excellence is a choice. So is Mediocrity
Excellence is a...
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The Quiet Crisis in the Indian Pharma Field Force
A MedicinMan Editorial based on the Poll framed by...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
Newsletter
Get important news delivered directly to your inbox and stay connected!